Neera Tanden

So, you know, I think that's a really important step.

I think the fact is that even Donald Trump recognizes Americans pay more for drugs, prescription drugs, than anywhere else in the world.

And we do that at the same time where we spend the most money on research for prescription drugs.

So consumers are paying on both ends.

And I'm glad he's trying to take some steps there.

Yes, I would say the Center for American Progress is an action-oriented think tank.

If America could start over again, there'd be a lot of benefits to single-payer.

It works well in other countries.

But it would be a radical transformation today.

So I we support I support more of a public option to people that would create competition for insurance companies.

And they'd actually have to compete on lowering costs vis-a-vis the government.

That would be great.

I mean, GLP-1 drugs are, they have many facets, one of which is drug companies just kind of discovered, like they basically struck gold with these drugs.

They weren't expecting to, you know, they invest to have this kind of benefit.

They are exceedingly expensive.

They have huge costs, huge health implications.

They would make Americans' lives much, much better on a whole range of issues.

We're discovering health, sleeping, heart conditions, as well as weight loss.

So it would be fantastic to get wide distribution and much cheaper price.

I think, you know, we're looking at things like a $20 an hour.